Regeneron Pharmaceuticals (REGN) Long-Term Deferred Tax (2011 - 2026)

Regeneron Pharmaceuticals has reported Long-Term Deferred Tax for 16 years, with the latest figure at $4.4 billion in Q2 2026.

• On a quarterly basis, Long-Term Deferred Tax rose 22.65% year-over-year to $4.4 billion in Q2 2026; TTM through Jun 2026 was $4.4 billion, a 22.65% increase from a year earlier, with the FY2025 full-year figure at $4.1 billion, up 23.03% from the prior year.
• Long-Term Deferred Tax was $4.4 billion for Q2 2026 at Regeneron Pharmaceuticals, up from $4.2 billion in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $4.4 billion in Q2 2026, with the low at $1.1 billion in Q1 2022.
• Average Long-Term Deferred Tax over 5 years is $2.8 billion, with a median of $2.8 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Long-Term Deferred Tax surged 100.79% in 2022, then climbed 21.73% in 2026.
• Over 5 years, Long-Term Deferred Tax stood at $1.7 billion in 2022, then soared by 49.41% to $2.6 billion in 2023, then advanced by 28.68% to $3.3 billion in 2024, then gained by 23.03% to $4.1 billion in 2025, then gained by 7.46% to $4.4 billion in 2026.
• The last three Long-Term Deferred Tax figures came in at $4.4 billion (Q2 2026), $4.2 billion (Q1 2026), and $4.1 billion (Q4 2025), per Business Quant data.